< Back to latest news & events

Event

IQPC Life Science IP 2019 – London

November 2019

Event date: 26th November 2019

HGF are sponsoring IQPC Life Science IP conference on 26-27 November in London with Partner Martyn Fish, Legal Director Michelle Davies and Partner Rachel Fetches attending.

Life Science IP 2019 will include a range of subjects around practical strategies for navigating the regulatory landscape and maximising the value of IP within Life Science, whilst sharing practical knowledge with speakers and colleagues.

Martyn Fish will be chairing day 1 and will be joining a panel debate ‘Alternative Means of IP Protection’.

He will be discussing ‘What alternative forms of protection to patent protection exist for the pharmaceutical industry: Can gene sequences be protected by copyright? Developments in the drug names? Design Right in chemical structures?’

  • Trade secrets
  • Trade marks – GSK’s Seretide inhaler
  • Copyright
  • Designs – claiming infringement for the copy of medicine designs.

Michelle Davies will be presenting on day 1 ‘Legal Risk Mitigation & Minimisation Across your Business’:

Issues across the business are inevitable, from the inadvertent disclosure of sensitive information through to adverse event reporting, patient interactions, manufacturing problems or product recall. Whilst some risks can be avoided, it is often the inappropriate handling of situations and panic responses made by a business that can cause the greatest damage.

Steps can be taken as a matter of good business practice to prevent or minimise business risk and exposure. With twelve years’ experience supporting business teams and functions within the pharmaceutical industry, Michelle will discuss her insights and the practical steps she deems most effective.

Latest updates

Polymorphs: Clearing the Inventive Step Hurdle at the European Patent Office (EPO)

Polymorphic forms of active pharmaceutical ingredients (APIs) can represent commercially valuable compound subject matter and can be critical to providing necessary drug product characteristics and performance. However, patenting polymorphs is …

Read article

IQPC Global US Exchange

HGF are proud ‘Silver Plus’ sponsors of the IQPC Global US Exchange, at the Austin Marriot South, Texas. The IQPC Global US Exchange will be held at the Austin Marriot …

Read article

Update on the Precision Breeding Act 2023: details emerge of the new simplified regulatory pathway for gene edited plant and animal derived food and feed products

The Genetic Technology (Precision Breeding) Act 2023 could come into force as early as spring 2025. It empowers the Food Standards Agency (FSA) to create a new simplified regulatory pathway …

Read article

Court of Appeal Decision Upholds Invalidity of Patent Due to Amendment Identifying Embodiment as Outside the Scope of the Claims

In a case that highlights the challenges arising due to post-grant amendments, and in particular interpretation of the claims in view of the description, the Court of Appeal in Ensygnia …

Read article

UPC Court of Appeal clarifies approach for interpreting claims with “obvious” errors

Alexion Pharmaceuticals, Inc. v Samsung Bioepis NL B.V. [UPC_CoA_402/2024] –Court of Appeal of the UPC (Grabinski, Blok, Gougé, Enderlin, Hedberg) – 20 December 2024 Alexion Pharmaceuticals, Inc. v Amgen Technology …

Read article

IP Ingredients: Winter Case Law Review 2024

As the nights draw in and the frenzy to finish everything off before the holiday season reaches its peak, it’s time to take a break, grab your favourite hot beverage …

Read article